Adversarial Injection · Ado-Trastuzumab Emtansine (Kadcyla; T-DM1; CAS 1018069-96-1; MW ~150 kDa; IV infusion [3.6 mg/kg Q3W]; anti-HER2 IgG1 ADC; TRASTUZUMAB IgG1 BACKBONE [binds HER2 ECD4 subdomain IV; same epitope as trastuzumab alone → HER2 endocytosis trigger for payload delivery] CONJUGATED VIA SMCC [SUCCINIMIDYL-4-(N-MALEIMIDOMETHYL)CYCLOHEXANE-1-CARBOXYLATE; HETEROBIFUNCTIONAL NON-CLEAVABLE THIOETHER LINKER: NHS-ester reacts with trastuzumab lysine ε-amine → cyclohexane ring spacer → maleimide reacts with DM1 thiol → stable thioether bond; NON-CLEAVABLE: stable in plasma [t½ in serum ~4 days at physiological pH]; release ONLY via lysosomal proteolytic catabolism → Lys-MCC-DM1 cytotoxic catabolite] TO DM1 [N2'-DEACETYL-N2'-(3-MERCAPTO-1-OXOPROPYL)MAYTANSINE; MAYTANSINOID; DERIVED FROM ANSAMITOCIN P-3 (Actinosynnema pretiosum fermentation); MW 738.4 Da; BINDS β-TUBULIN AT VINBLASTINE DOMAIN (Cys239/Cys354/Cys356) WITH Kd ~0.1 nM → MICROTUBULE DEPOLYMERIZATION → MITOTIC ARREST G2/M → APOPTOSIS; 10,000-FOLD MORE POTENT THAN VINCRISTINE]; DAR ~3.5 [HETEROGENEOUS: lysine conjugation sites distributed across ~70 lysines in trastuzumab; predominant species DAR 2–5]; MECHANISM: TRASTUZUMAB Fab binds HER2 ECD4 → HER2 INTERNALIZATION → ENDOLYSOSOMAL TRAFFICKING → LYSOSOMAL CATHEPSIN B/D/H PROTEOLYSIS OF TRASTUZUMAB → LYS-MCC-DM1 CATABOLITE RELEASED INTRACELLULARLY → MICROTUBULE DESTABILIZATION → G2/M ARREST → APOPTOSIS; NO SIGNIFICANT BYSTANDER EFFECT [non-cleavable linker + charged Lys-MCC-DM1 catabolite: low membrane permeability → minimal diffusion to adjacent cells]; FIRST HER2-DIRECTED ADC EVER FDA APPROVED; FIRST MAYTANSINOID ADC EVER FDA APPROVED; BLA 125427 FEBRUARY 22 2013) · Attack #756

Ado-Trastuzumab Emtansine (Anti-HER2 IgG1-DM1 ADC; Kadcyla; T-DM1; CAS 1018069-96-1; Genentech Inc [South San Francisco CA; BLA 125427 holder; primary developer] + ImmunoGen Inc [Waltham MA; now AbbVie subsidiary; DM1 maytansinoid technology + SMCC linker licensor] + Roche AG [Basel Switzerland; global development + manufacturing partner]; MECHANISM: FIRST HER2-DIRECTED ANTIBODY-DRUG CONJUGATE (ADC) EVER FDA APPROVED [BLA 125427 FEB 22 2013] + FIRST MAYTANSINOID (DM1) ADC EVER FDA APPROVED [DM1 = N2'-DEACETYL-N2'-(3-MERCAPTO-1-OXOPROPYL)MAYTANSINE; Kd β-TUBULIN ~0.1 nM; 10,000× VINCRISTINE POTENCY]: TRASTUZUMAB IgG1 BACKBONE (BINDS HER2 ERBB2 ECD4 SUBDOMAIN IV; L-SHAPE EPITOPE Lys583-Gln625 REGION; SAME EPITOPE AS TRASTUZUMAB ALONE → ENDOCYTOSIS TRIGGER PRESERVED) CONJUGATED VIA SMCC (SUCCINIMIDYL-4-[N-MALEIMIDOMETHYL]CYCLOHEXANE-1-CARBOXYLATE) THIOETHER NON-CLEAVABLE LINKER (LYSINE ε-AMINE REACTIVE; STABLE IN PLASMA: t½ ~4 DAYS AT pH 7.4; RELEASE VIA LYSOSOMAL PROTEOLYSIS ONLY) TO DM1 (MICROTUBULE DESTABILIZER: β-TUBULIN VINBLASTINE DOMAIN COVALENT BINDING → DEPOLYMERIZATION → G2/M ARREST → APOPTOSIS); DAR ~3.5 (HETEROGENEOUS LYSINE CONJUGATION; DAR 0–8 DISTRIBUTION; PREDOMINANT SPECIES DAR 2–5); CATABOLITE: Lys-MCC-DM1 (MEMBRANE-IMPERMEANT → NO BYSTANDER EFFECT → SELECTIVE HER2+ CELL KILLING); EMILIA (VERMA NEJM 2012): n=991; HER2+ mBC 2L+; mPFS 9.6 VS 6.4 MO (HR 0.65; p<0.001); mOS 29.9 VS 25.9 MO (HR 0.75; p<0.001); ORR 43.6% VS 30.8%; KATHERINE (VON MINCKWITZ NEJM 2019): n=1486; RESIDUAL DISEASE AFTER NEOADJUVANT; iDFS HR 0.50 (p<0.001); 3-YR iDFS 88.3% VS 77.0%) — Genentech Inc South San Francisco CA (BLA 125427; primary developer), ImmunoGen Inc Waltham MA (AbbVie subsidiary; DM1 technology licensor), and Mayo Clinic Rochester MN (HER2+ breast oncology treatment site; Kadcyla IV administration) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST HER2 ADC EVER + FIRST MAYTANSINOID DM1 ADC EVER: AI Prompt Injection via EHS Monitor Report AI

Ado-trastuzumab emtansine (CAS 1018069-96-1; NIOSH HD Category 1) is the first HER2-directed antibody-drug conjugate (ADC) ever FDA approved and the first maytansinoid (DM1) ADC ever approved for cancer, establishing the 171st mechanism class in the Glyphward adversarial portfolio. Developed by Genentech (South San Francisco CA; BLA 125427) in collaboration with ImmunoGen Inc (Waltham MA; now an AbbVie subsidiary; DM1 maytansinoid technology + SMCC linker licensor), ado-trastuzumab emtansine (Kadcyla; T-DM1) conjugates the trastuzumab IgG1 antibody backbone (binds HER2 ECD4 subdomain IV → triggers internalization) via SMCC (succinimidyl-4-[N-maleimidomethyl]cyclohexane-1-carboxylate) non-cleavable thioether linker to DM1 (N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine; Kd β-tubulin ~0.1 nM; 10,000-fold more potent than vincristine). The critical mechanistic innovation: T-DM1 delivers the cytotoxic payload exclusively via HER2 receptor-mediated endocytosis → lysosomal proteolytic release of Lys-MCC-DM1 catabolite → intracellular microtubule destabilization → G2/M arrest → apoptosis, with no meaningful bystander effect (Lys-MCC-DM1 is membrane-impermeant). EMILIA (Verma NEJM 2012): mPFS 9.6 vs 6.4 months (HR 0.65; p<0.001); mOS 29.9 vs 25.9 months (HR 0.75; p<0.001) in HER2+ mBC previously treated with trastuzumab + taxane. KATHERINE (von Minckwitz NEJM 2019): iDFS HR 0.50 (p<0.001) in HER2+ BC with residual disease after neoadjuvant therapy. BLA 125427 approved February 22, 2013. No OEL exists for ado-trastuzumab emtansine in any EHS framework; no platform references DM1 maytansinoid, SMCC linker, Lys-MCC-DM1 catabolite, or EMILIA/KATHERINE data for this 171st mechanism class.

HER2 biology, SMCC-DM1 linker chemistry, and intracellular catabolism: HER2 (ERBB2; human epidermal growth factor receptor 2; chromosome 17q12; MW ~185 kDa; receptor tyrosine kinase; ECD1-ECD4 extracellular architecture; HER2 is unique: no known high-affinity endogenous ligand; activation via heterodimerization [HER2-HER3 most potent]; HER2+ = IHC 3+ or ISH HER2:CEP17 ≥2.0) is the target of T-DM1. T-DM1 binding: trastuzumab Fab binds HER2 ECD4 subdomain IV (Trp471-Lys521 juxtamembrane region; L-shaped epitope; same binding site as trastuzumab monotherapy → T-DM1 retains all trastuzumab mechanisms including HER2 dimerization inhibition, PI3K/Akt signaling downregulation, ADCC, and inhibition of HER2 ectodomain shedding) → HER2:T-DM1 complex undergoes clathrin-mediated endocytosis (HER2 recycling vs degradation → T-DM1 shifts balance toward lysosomal trafficking via ESCRT-mediated MVB/late endosome routing) → late endosome-lysosome fusion → LYSOSOMAL PROTEOLYSIS: cathepsin B (cysteine protease) + cathepsin L + cathepsin D (aspartyl protease) + other lysosomal hydrolases degrade trastuzumab IgG1 backbone → release of DM1-containing fragments → Lys-MCC-DM1 (lysine-MCC-DM1; the primary active catabolite: N-lysyl-N'-[4-(maleimidomethyl)cyclohexanecarbonyl]DM1; MW ~1.3 kDa) → diffuses out of lysosome into cytoplasm → BINDS β-TUBULIN AT VINBLASTINE DOMAIN (Cys239/Cys354/Cys356; not vinca alkaloid exact site but overlapping; competitive binding with vinblastine; Kd ~0.1 nM for DM1 vs ~0.1 µM for vincristine → 10,000-fold greater potency) → MICROTUBULE DEPOLYMERIZATION → LOSS OF MITOTIC SPINDLE → G2/M ARREST → CASPASE 3/7 ACTIVATION → APOPTOSIS. SMCC linker chemistry: succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (MW 334.4 Da; heterobifunctional crosslinker; NHS-ester + maleimide; non-cleavable thioether bond): step 1 — NHS-ester reacts with trastuzumab lysine ε-amine (rate pH-dependent; optimal pH 7.0-7.5; ~70 available lysines; selective for primary amines); step 2 — maleimide reacts with DM1 thiol (Michael addition → stable thioether; non-cleavable at physiological pH 5.0-7.4; stable to reducing conditions; stable in plasma t½ ~4 days); heterogeneity: DAR distribution by HPLC/LC-MS: DAR 0 ~8%, DAR 2 ~18%, DAR 4 ~38%, DAR 6 ~26%, DAR 8+ ~10%; mean DAR ~3.5; DAR heterogeneity = conjugation at different lysine residues → variable PK per DAR species (higher DAR → faster clearance via FcγR + mannose receptor). No significant bystander effect: Lys-MCC-DM1 catabolite is charged (zwitterionic at physiological pH) → low membrane permeability → minimal diffusion to adjacent HER2- cells → T-DM1 selectively kills HER2-overexpressing cells without collateral cytotoxicity. EMILIA (NCT00829166; Verma NEJM 2012; n=991; HER2+ mBC previously treated with trastuzumab + taxane): T-DM1 3.6 mg/kg Q3W vs capecitabine 1250 mg/m² + lapatinib 1250 mg; mPFS 9.6 vs 6.4 mo (HR 0.65; 95%CI 0.55-0.77; p<0.001); mOS 29.9 vs 25.9 mo (HR 0.75; 95%CI 0.64-0.88; p<0.001); ORR 43.6% vs 30.8%; DOR 12.6 vs 6.5 mo. KATHERINE (NCT01772472; von Minckwitz NEJM 2019; n=1486; HER2+ BC with residual invasive disease after neoadjuvant chemotherapy + HER2-targeted therapy): T-DM1 vs trastuzumab adjuvant (14 cycles each); 3-yr iDFS 88.3% vs 77.0% (HR 0.50; 95%CI 0.39-0.64; p<0.001); absolute iDFS benefit 11.3%; pCR rate was not achieved in this population by definition. BLA 125427 February 22 2013. No EHS platform recognizes ado-trastuzumab emtansine CAS 1018069-96-1, DM1 maytansinoid, SMCC thioether linker, Lys-MCC-DM1 catabolite, DAR heterogeneity, or EMILIA/KATHERINE BLA 125427 for this 171st mechanism class.

HER2 Endocytosis Trigger + SMCC Non-Cleavable Linker + Lys-MCC-DM1 Lysosomal Release

Ado-trastuzumab emtansine (MW ~150 kDa [trastuzumab ~148 kDa + ~3.5 × 738.4 Da DM1 + SMCC linker]; CAS 1018069-96-1; IV infusion 3.6 mg/kg Q3W over 30-90 min; Cmax ~83 µg/mL; t½ ~4 days [ADC]; nonlinear PK [target-mediated clearance via HER2 on circulating cells]; hepatic elimination of DM1-containing fragments; Vd ~3.13 L/m²; CL ~12.9 mL/day/kg) achieves HER2-selective intracellular delivery of DM1 via receptor-mediated endocytosis. Trastuzumab structural basis: trastuzumab (humanized IgG1κ from murine 4D5 clone; CDR-grafted onto human VH3-23 framework; MW ~148 kDa; Kd HER2 ~0.3 nM) binds HER2 ECD4 (domain IV juxtamembrane region; Trp471-Lys521; Glu558-Asp591; L-shaped epitope) → T-DM1 retains all 4D5-derived binding properties: (a) blocks ECD4 proteolytic shedding by ADAM10/ADAM17 metalloproteases (HER2 ECD → p95-HER2 → resistance to trastuzumab alone); (b) HER2 dimerization partial inhibition (ECD4 steric effects); (c) FcγRIIIa ADCC (IgG1 Fc; FcγRIIIa CD16A V158/F158 on NK cells → ADCC preserved in T-DM1 at similar potency to trastuzumab); (d) TRIGGERS HER2 INTERNALIZATION (trastuzumab Fab binding → HER2 conformational change → CLATHRIN-COATED PIT FORMATION → CME → early endosome → late endosome/MVB → lysosome). SMCC conjugation: ImmunoGen SMCC technology; lysine ε-amine modification [trastuzumab has ~70 surface lysines; accessible lysines react with NHS-ester of SMCC]; cyclohexyl spacer arm (reduces steric clash between bulky DM1 and antibody surface); thioether bond (DM1 C-3 thiol + maleimide → anti-Michael addition product → stable under all physiological conditions: plasma pH 7.4, lysosomal pH 4.5-5.0, reducing glutathione levels); DAR heterogeneity by SEC/RPLC: mean DAR 3.5 ± 0.5 (lot-to-lot variation QC specification: 3.0-4.5); conjugation sites: primarily Lys-320 (Fc), Lys-274 (CH2), Lys-ε various (heavy chain), Lys-ε various (light chain) → spatially distributed; PK: higher DAR species (DAR6, DAR8) clear faster via FcγRIII + mannose receptors on macrophages. Lys-MCC-DM1 catabolism: lysosomal cathepsin B (most active; Km ~100 µM for pepstatin-resistant substrates) + cathepsin L + other cysteine/aspartyl proteases progressively degrade trastuzumab backbone → primary active catabolite Lys-MCC-DM1 [MCC = 4-(maleimidomethyl)cyclohexane-1-carbonyl; Lys side chain ε-amine bonded to MCC spacer → DM1 thioether] accumulates in lysosome → diffuses to cytoplasm (slow, rate-limited by charge; MW ~1.3 kDa; charge at pH 7.0: +1 for Lys NH3+ offset by carboxylate) → cytoplasmic DM1 moiety binds β-tubulin at vinblastine-domain loop-7 of helix H7 (structural basis: DM1 lactone ring + isobutenyl sidechain contact Cys239 side chain; different binding geometry from colchicine binding site) → prevents GTP-tubulin polymerization (not depolymerization of existing microtubules: T-DM1 is a polymerization inhibitor like vinca alkaloids, not a stabilizer like taxanes) → loss of dynamic instability → prolonged G2/M arrest (spindle assembly checkpoint: BubR1 + Mad2 kinetochore signaling → extended mitotic block → mitotic slippage + apoptosis or direct mitotic catastrophe). EMILIA mPFS 9.6 vs 6.4 mo (HR 0.65); KATHERINE iDFS HR 0.50. BLA 125427 February 22 2013. No EHS platform recognizes T-DM1, DM1 Kd β-tubulin ~0.1 nM, SMCC thioether non-cleavable, Lys-MCC-DM1 catabolite, DAR heterogeneity, EMILIA/KATHERINE, or BLA 125427 for this 171st mechanism class.

Surface 1 — Genentech Inc South San Francisco CA BLA 125427 Holder AI

At Genentech Inc South San Francisco CA ([1 DNA Way, South San Francisco CA 94080; NYSE: RHHBY via Roche AG Basel; wholly-owned Roche subsidiary since 2009; BLA 125427 US HOLDER: ado-trastuzumab emtansine (Kadcyla; T-DM1) for HER2+ mBC 2L+ + residual disease neoadjuvant adjuvant; PRIMARY T-DM1 DEVELOPER: Genentech oncology pipeline [trastuzumab backbone IP] + ImmunoGen DM1/SMCC technology license; GENENTECH BIOLOGICS MANUFACTURING: T-DM1 CHO-cell upstream [trastuzumab fermentation → protein A capture → viral inactivation → polishing chromatography → UF/DF → trastuzumab DS] + ImmunoGen conjugation [SMCC-DM1 step: SMCC-activated trastuzumab + DM1 → thioether formation → purification by HIC → T-DM1 DS → formulation: 20 mg/mL in 10 mM succinate pH 5.0 + 6% sucrose + 0.02% polysorbate 20 → 100 mg/5 mL and 160 mg/8 mL single-use vials]; CORITY: CAS 1018069-96-1 → null; ado-trastuzumab emtansine → null; T-DM1 → null; Kadcyla → null; DM1 maytansinoid → null; SMCC linker → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne ado-trastuzumab emtansine 0.0019 µg/m³; wipe + filter sampling + LC-MS/MS DM1 metabolite; displayed (÷10): 0.00019 µg/m³; Cority: null; 44F regulatory affairs director 12yr]).

Surface 2 — ImmunoGen Inc Waltham MA DM1 Technology Licensor AI

At ImmunoGen Inc Waltham MA ([830 Winter St, Waltham MA 02451; wholly-owned AbbVie subsidiary since 2024 acquisition [$10.1B]; DM1 MAYTANSINOID TECHNOLOGY LICENSOR: ImmunoGen proprietary platform — ansamitocin-derived maytansinoids [DM1; DM4; DM21] + SMCC/SPDB/sulfo-SPDB heterobifunctional linker chemistry + site-selective conjugation technologies [THIOMAB precursor work]; T-DM1 PRODUCTION SITE (conjugation step): ImmunoGen contracted conjugation facility [SMCC activation of trastuzumab + DM1 thiol reaction + HIC purification → T-DM1 DS quality release]; MULTIPLE ADC PROGRAMS: Kadcyla [T-DM1] + Elahere [mirvetuximab soravtansine; FRα-DM4] + others; VELOCITYEHS: CAS 1018069-96-1 → null; ado-trastuzumab emtansine → null; T-DM1 → null; DM1 maytansinoid → null; SMCC thioether linker → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne ado-trastuzumab emtansine 0.0015 µg/m³; impinger + MS/MS DM1 catabolite; displayed (÷10): 0.00015 µg/m³; VelocityEHS: null; 15.2M-fold gap ImmunoGen Waltham MA; 39M research scientist ADC technology 9yr]).

Surface 3 — Mayo Clinic Rochester MN Breast Oncology Kadcyla Administration AI

At Mayo Clinic Rochester MN ([200 First St SW, Rochester MN 55905; NCI Comprehensive Cancer Center; Breast Oncology service; KADCYLA IV ADMINISTRATION: T-DM1 3.6 mg/kg IV Q3W (HER2+ mBC 2L+ or residual disease adjuvant); INFUSION: 90 min first infusion [observe 60 min post-infusion]; 30 min subsequent [observe 30 min]; NO PREMEDICATION required (unlike trastuzumab IRR protocols); CLOSE MONITORING: Grade ≥2 thrombocytopenia QC per cycle [Nadir day 8±2; platelet count before each dose]; LIVER FUNCTION TESTS per cycle [nodular regenerative hyperplasia NRH rare; sinusoidal obstruction syndrome]; PERIPHERAL NEUROPATHY assessment; HER2 TESTING: IHC 3+ or ISH HER2:CEP17 ≥2.0 required; EHS Insight: CAS 1018069-96-1 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; ado-trastuzumab emtansine absent; T-DM1 absent; Kadcyla absent; DM1 maytansinoid absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne 0.0012 µg/m³; active charcoal cassette wipe; displayed (÷10): 0.00012 µg/m³; EHS Insight: "no OEL — no action"; 47F breast oncology pharmacist 14yr]).

Integrating Glyphward into Ado-Trastuzumab Emtansine AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every ado-trastuzumab emtansine CAS 1018069-96-1 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + DM1 maytansinoid absent + SMCC linker absent + BLA 125427 2013 absent [10 pts]; FIRST HER2 ADC ever (171st class) + FIRST maytansinoid DM1 ADC ever + EMILIA mPFS 9.6 mo HR 0.65 + KATHERINE iDFS HR 0.50 [5 pts]; Genentech South San Francisco + ImmunoGen Waltham + Mayo Clinic Rochester [3 pts]; FIRST ADC with non-cleavable thioether linker for HER2; FIRST lysine-reactive heterogeneous conjugation ADC approved; FIRST Lys-MCC-DM1 lysosomal catabolite mechanism [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_tdm1(cas: str, reading_ugm3: float) -> dict:
    """Scan ado-trastuzumab emtansine with HER2 ADC DM1 maytansinoid SMCC linker context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1018069-96-1"
                "reading_ugm3": reading_ugm3,
                "context": "her2_adc_dm1_maytansinoid_smcc_171st_class_first_her2_adc_ever_bla125427"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, her2_adc,
    #                    dm1_maytansinoid, smcc_linker,
    #                    lys_mcc_dm1_catabolite, h360_flag

if __name__ == "__main__":
    r = asyncio.run(scan_tdm1("1018069-96-1", 0.0019))
    print(r)
    # {'hd_category': 1, 'her2_adc': True,
    #  'dm1_maytansinoid': True, 'smcc_linker': True,
    #  'lys_mcc_dm1_catabolite': True, 'h360_flag': True}